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The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal
cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity. Patients
received capecitabine 2000mg (4 500mg tablets) twice daily on days 1–14 every 3 weeks. They were reviewed weekly during the
first cycle and then three weekly for safety assessment. Eligibility criteria were advanced/metastatic colorectal cancer, p2 prior
chemotherapy regimens, ECOG performance status 0–2 and life expectancy 412 weeks. A total of 60 patients were enrolled and
55 were evaluable for efficacy. The median age was 72 years and 63% of patients had a performance status of 1 or 2. Confirmed
tumour responses were reported in 15 patients (28%; 95% confidence interval (CI), 15.7–40.3%). The median time to disease
progression was 4.9 months and median overall survival was 11.2 months. The median ratio of fixed dose to body surface area
(BSA)-calculated dose was 88% (range 65–108%). Significant myelosuppression was not observed. Grade 2/3 treatment-related
adverse events were diarrhoea (34%), fatigue (27%), stomatitis (15%) and hand–foot syndrome (22%). Dose reduction due to
adverse events was required in 16 patients (29%) and multiple reductions in five patients (9%). There was no grade 3/4
haematological toxicity, any grade 4 adverse events or treatment-related deaths. Patients with higher pretreatment levels of serum
folate experienced significantly greater toxicity (P¼0.02, CI: 1.0–1.2) during cycle 1 and over the entire treatment period (P¼0.04,
CI: 1.0–1.3). Pretreatment homocysteine concentrations did not predict for toxicity. In conclusion, fixed-dose capecitabine appears
to have similar efficacy and safety compared to the currently recommended dose schedule based on body surface area and simplifies
drug administration. A high pretreatment folate may be predictive of increased toxicity from capecitabine.
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5-Fluorouracil (5-FU) has been the mainstay of treatment of
patients with advanced or metastatic colorectal cancer, and
remains an integral component of modern combination regimens.
As a single agent, 5-FU improves median survival by approxi-
mately 6 months (Midgley and Kerr, 1999). Attempts at producing
more effective 5-FU regimens have been made, using continuous
5-FU infusion or biomodulation with agents such as Leucovorin
(LV; folinic acid), although improvements in survival have been
marginal (Schmoll et al, 1999). However, the addition of oxali-
platin and irinotecan to 5-FU has increased response rates and
median survival compared to 5-FU alone (de Gramont et al, 2000;
Douillard et al, 2000; Giacchetti et al, 2000; Saltz et al, 2000). These
regimens, however, are associated with increased toxicity and may
not be suitable for all colorectal cancer patients. In addition,
infusional regimens of 5-FU often require the use of an indwelling
central venous catheter, which can be associated with a number of
complications, for example, thrombosis, infection, pneumothorax
and bleeding. The use of indwelling central venous catheter is also
associated with increased hospital resource utilisation (Ardalan
and Flores, 1995; Schmoll, 1996; Verso and Agnelli, 2003).
Capecitabine is an oral fluoropyrimidine that preferentially
delivers 5-FU to the tumour via a three-step enzymatic conversion,
the final step being catalysed by thymidine phosphorylase, which
has a higher activity within the tumour compared with healthy
tissue (Miwa et al, 1998).
The current recommended dose of capecitabine for the
treatment of metastatic colorectal cancer is 1250mgm
 2 twice
daily for 14 days followed by a 7-day rest period. Criticism has
been levelled at BSA as a method of calculating doses of cytotoxic
agents. Correlation between BSA and physiological functions, such
as hepatic and renal function, is weak or nonexistent. Only cardiac
output has been shown to correlate with BSA (Sawyer and Ratain,
2001). Gurney (1996) argues for the introduction of a ‘prime’ fixed
dose to be determined for each drug. This prime dose would then
be modified rationally using known covariates of drug clearance
such as renal or hepatic function, or following an initial dose
administration based on the extent of toxicity experienced.
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sCapecitabine is available in either 500 or 150mg tablet size and
consequently dosing by BSA can be impractical and the dose is
frequently rounded off to a convenient number of tablets. In
addition, pharmacokinetic studies demonstrate that when capeci-
tabine doses were determined by BSA, there were large inter-
patient variations in the pharmacokinetics of capecitabine and
its metabolites (27–89%). This was thought to be primarily due to
variability in the activity of metabolic enzymes (Reigner et al,
2001). Furthermore, in a bioequivalence study by Cassidy et al
(1999), no clinically significant effect was observed between BSA
and the pharmacokinetics of capecitabine and its metabolites.
Therefore, in the current study, we planned to evaluate the efficacy
and safety of fixed-dose capecitabine given at 2000mg (4 500mg
tablets) twice daily on days 1–14 every 3 weeks. For instance, an
average patient would have a BSA of 1.6m
2 that corresponds to a
capecitabine dose of 2000mg daily. This fixed dose was considered
to be appropriate for this study.
A number of clinical studies have illustrated that pretreatment
levels of folate and homocysteine are predictive for both tumour
response and toxicty in patients treated with either thymidylate
synthase (TS) inhibitors or folate antagonists (Bunn et al, 2001;
Calvert, 2002; Niyikiza et al, 2002). Increased amounts of
exogenous folate leads to enhanced TS inhibition and stability of
the ternary complex formed between the enzyme, deoxyuridine
monophosphate and the folate cofactor (Pinedo and Peters, 1988).
Previous murine studies have indicated that folate levels may
predict for the cytotoxic efficacy of 5-FU (van der Wilt et al, 2001).
Serum and red cell folate and plasma homocysteine each reflect
different aspects of a patient’s folate status. Therefore, the relation-
ships between folate and homocysteine levels with both response
and toxicity following capecitabine treatment were evaluated.
PATIENTS AND METHODS
Patients
Patients were eligible for entry into the study if they had locally
advanced or metastatic colorectal cancer with measurable or
evaluable disease. Patients could have previously received up to
two prior chemotherapy regimens for metastatic disease. If
administered, adjuvant therapy should have been completed X6
months prior to study entry. Histological or cytological confirma-
tion of colorectal adenocarcinoma was required. Patients had to
be at least 18 years of age and have a life expectancy 412 weeks.
ECOG performance status (PS) was required to be between 0 and 2.
Patients were not included if they had active or extensive brain
metastases, active systemic infection, inflammatory bowel disease,
unstable cardiac disease or untreated vitamin B12 deficiency.
Patients who were pregnant or actively lactating were excluded.
Patients had to be able to be changed from warfarin to enoxaparin
sodium (Kolesar et al, 1999). Patients were not enrolled if initial
evaluations revealed significant abnormalities in neutrophils
(o1.5 10
9/l), platelets (o100 10
9/l), serum creatinine or serum
bilirubin (41.5 upper limit of normal), and ALT, AST or
alkaline phosphatase (43 upper limit of normal).
The study received prior local ethical board approval and was
conducted according to the Declaration of Helsinki and its
subsequent amendments. All patients gave written informed
consent prior to participation in the trial.
Study treatment
The study was conducted at three different hospitals in New South
Wales, Australia, each of which followed the same protocol and
was coordinated from a single centre. Capecitabine was adminis-
tered orally at a fixed dose of 2000mg twice daily on days 1–14
every 3 weeks. Capecitabine doses were given approximately 12h
apart and taken with water within 30min following ingestion of
food. Treatment with capecitabine was continued until the
scheduled assessment at 30 weeks, or until the development of
progressive disease or unacceptable toxicity. In responding
patients, treatment could be continued beyond 30 weeks at the
discretion of the investigator.
Treatment modifications
Treatment interruption or dose reduction was not indicated for
grade 1 toxicity National Cancer Institute Common Toxicity
Criteria (CTC) version 2.0 (National Cancer Institute: Common
toxicity criteria). Treatment was interrupted in cases of grade 2
toxicity or worse, and was not resumed until toxicity resolved or
improved to grade 1. When treatment was resumed, capecitabine
doses were reduced as follows: by 25% (1000mg) for patients who
experienced a second occurrence of a given grade 2 nonhaema-
tological toxicity, or a first occurrence of a haematological toxicity
or any grade 3 toxicity; or by 50% (2000mg) for patients who
experienced a grade 3 haematological toxicity. Treatment was
discontinued if a given toxicity occurred despite dose reduction or
for grade 4 toxicity.
Evaluation of patients
Complete history was recorded, full physical examination per-
formed and blood samples were collected at baseline. Baseline
blood analyses included full blood count (FBC), biochemistry,
liver function tests (LFTs), vitamin B12, carcinoembryonic antigen
(CEA), serum and red cell folate and plasma homocysteine. Serum
and red cell folate were measured in a central laboratory using
National Committee for Clinical Laboratory Standards (NCCLS)
procedures. Serum and red cell folate were measured using a
competitive binding receptor assay (Access immunoassay, Beck-
man and Coulter Inc., Gladesville, NSW, Australia). Samples were
not batched, but analysed as patients were enrolled.
Baseline CT imaging of the chest, abdomen and pelvis was
obtained within 3 weeks of treatment commencement. At the start
of each treatment cycle, history and physical examination were
repeated and blood samples were taken for FBC, biochemistry,
LFTs and CEA. Patients were reviewed weekly during cycle one
and then every 3 weeks for safety assessment. All safety evaluations
were graded according to the NCI-CTC except hand–foot
syndrome (HFS). Hand–foot syndrome was classified as grade 1
(numbness, dysaesthesia, painless swelling or erythema not
disrupting normal activities), grade 2 (painful erythema with
swelling or affecting daily living activities) or grade 3 (moist
desquamation, ulceration, blistering, severe pain or any symptoms
leading to an inability to work or to perform daily living activities)
(Blum et al, 1999). Tumour response was assessed after every two
cycles with repeat CT chest, abdomen and pelvis. Tumour response
or progression was recorded using the RECIST criteria (Therasse
et al, 2000).
Statistics
For analyses, toxicity was grouped and analysed as grade 0 and 1,
grade 2 and 3 or as grade 4. The association between the presence
of a serious adverse event (grade 2 or 3) both during cycle 1 and
for the whole course of treatment and the following parameters
was determined using logistic regression: gender, PS, number of
sites of metastases, prior pelvic radiotherapy, creatinine clearance,
homocysteine, serum folate, red cell folate, serum vitamin B12 and
serum albumin. The odds ratio and its 95% confidence interval
(95% CI) were used to quantify the extent of any association.
Kaplan–Meier survival curves were used to illustrate the distribu-
tions of the time to progression and overall survival.
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sRESULTS
Patients and treatment
A total of 60 patients were enrolled from three centres in Australia
between January 2002 and August 2003. Four patients were
excluded from analysis as they were not dosed according to
protocol and one patient withdrew consent. Therefore, the efficacy
and safety analyses included 55 patients.
The demographic and clinical characteristics of the patients are
summarised in Table 1. The median age of patients at enrolment
was 72 years, and 35 (63%) patients had a performance status of 1
or 2. A total of 13 patients (24%) had received prior adjuvant
chemotherapy with 5-FU/LV and two patients (4%) had received
prior chemotherapy for metastatic disease (one with oxaliplatin/
5-FU and the other with irinotecan/5-FU). Six patients (11%) had
received prior pelvic radiotherapy.
Efficacy
At the time of analysis, 48 patients had died. The cause of death in
all patients was disease progression. The best tumour response
over the entire treatment period for all treated patients is shown in
Table 2. Two patients were not evaluable, as they did not have
radiological follow-up. The overall response rate in evaluable
patients was 28% (95% CI: 15.7–40.3). In all, 17 patients (32%,
95% CI: 19.2–44.8) had stable disease while the remaining 21
patients (40%, 95% CI: 26.5–53.5) had disease progression.
Responses were observed in three (23%) of the patients who had
received prior 5-FU-based adjuvant therapy. Median survival was
11.2 months (95% CI: 8.7–13.7) and median time to disease
progression was 4.9 months (95% CI: 1.5–8.2).
At the time of analysis, five patients were still receiving
capecitabine. The median duration of therapy with capecitabine
was 97 days and the median number of cycles received was 6.5. The
median dose intensity received was 100% (range 25–114%). The
median BSA value of the enrolled patient cohort was 1.8m
2.
Assuming the normal recommended dose of capecitabine
(1250mgm
 2 twice daily on days 1–14 every 3 weeks) had been
used, the total dose calculated on BSA should have been 63350mg
during the first cycle of therapy. The median total flat dose
received by patients in cycle 1 was 56000mg. Therefore, the
median ratio of fixed-dose to BSA-calculated dose was 88% (range
65–108%). Thus, patients received a median dose 12% lower than
the BSA-calculated dose.
Safety
The most common treatment-related adverse events are reported
in Table 3. Overall, fixed-dose capecitabine was well tolerated with
no grade 4 nonhaematological or grade 3/4 haematological adverse
events recorded. Fatigue, HFS and diarrhoea were the predominant
adverse events reported. Overall, adverse events were reversible
and manageable with interruption of dosing and dose reduction.
A single dose reduction because of toxicity was required in 16
patients (29%) and multiple reductions were required in five
patients (9%). Of the patients that had received prior pelvic
radiotherapy, one patient had a 1-week delay in treatment due to
grade 3 diarrhoea. The most common adverse event resulting in
dose reduction was HFS (22%) and treatment was delayed in 19
(35%) patients. Adverse events led to the cessation of treatment in
eight patients (15%). The most frequent adverse event leading to
discontinuation was diarrhoea. There were no adverse-event-
related deaths during the study.
Predictors of toxicity
Baseline laboratory test results were not available for all patients
(Table 4). The relationship between baseline levels of creatinine
clearance, CEA, homocysteine, red cell and serum folate, serum
vitamin B12 and albumin and toxicity during cycle 1, and for the
whole treatment course were assessed. No significant relationship
was seen between toxicity and creatinine clearance (P¼0.8), CEA
Table 1 Demographic and clinical characteristics (N¼55)
Parameter No. of patients (%)
Male 35 (64%)
Median age, years (range) 72 (42–86)
Median bodyweight, kg (range) 71 (44.3–117.8)
Performance status
0 20 (36%)
1 32 (58%)
2 3 (5%)
Primary tumour site
Colon 39 (71%)
Rectal 15 (27%)
Unknown 1 (2%)
No. of metastatic sites
1 30 (55%)
2 15 (27%)
X3 10 (18%)
Prior adjuvant chemotherapy 13 (24%)
Prior chemotherapy for metastatic disease 2 (4%)
Prior pelvic radiotherapy 6 (11%)
Table 2 Radiological response in the evaluable population (N¼53)
Response No. of patients (%)
Complete response 0
Partial response 15 (28)
Stable disease 17 (32)
Progressive disease 21 (40)
Table 3 Adverse events in the total population (N¼55)
% of patients
Grade 2 Grade 3
Fatigue 25 2
Hand–foot syndrome 11 11
Stomatitis 15 0
Diarrhoea 25 9
Nausea and vomiting 9 2
Anaemia 13 0
Liver toxicity 4 0
Table 4 Baseline laboratory test values
Parameter (no. of patients with available results) Median (range)
Creatinine clearance, ml/min (n¼55) 75.41 (45.12–165.1)
Red cell folate, nmol/l (n¼28) 633.5 (358–1841)
Serum folate, nmol/l (n¼38) 16.65 (6.6–45.4)
Albumin, g/l (n¼51) 39 (29–47)
Vitamin B12, pmol/l (n¼38) 283 (187–830)
Homocysteine, mmol/l (n¼36) 12 (8–47)
CEA (n¼50) 52.8 (1.7–3225)
CEA¼carcinoembryonic antigen.
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vitamin B12 (P¼0.3) and albumin (P¼0.9). A significant
association was observed between high pretreatment serum folate
and worse toxicity (n¼38, P¼0.02, CI: 1.0–1.2). On further
analysis, elevated levels of pretreatment serum folate were
associated with a higher incidence of grade 2/3 diarrhoea
(P¼0.001) and grade 2/3 nausea and vomiting (P¼0.032)
compared to grade 0/1 toxicity. For serum folate levels less than
17.96nmoll
 1, no significant toxicity was seen. When assessing for
potential predictors of toxicity over the entire treatment period,
serum folate remains significant (P¼0.04, CI: 1.0–1.2).
DISCUSSION
In the current study, we demonstrated that fixed dose capecitabine
can be safely and effectively used as an alternative to conventional
BSA-corrected dosing strategy in the treatment of metastatic
colorectal cancer. Furthermore, we have shown that a raised serum
folate level may be predictive of worse toxicity, in particular
diarrhoea, nausea and vomiting.
With respect to efficacy, the overall response rate was 28%, time
to disease progression was 4.9 months and median overall survival
was 11.2 months. These results are similar to the combined results
of phase III studies of the currently recommended BSA-calculated
dosage schedule for capecitabine, which recruited over 1200
patients: overall response rate of 26%, time to disease progression
of 4.6 months and overall survival of 12.9 months (Hoff et al, 2001;
Van Cutsem et al, 2001, 2004). In comparing these results, it is
essential to compare and contrast the clinical and demographic
characteristics of the patient populations treated. Patients in the
phase III studies received capecitabine exclusively as first-line
treatment for metastatic disease, and 24% had received prior 5-FU-
based adjuvant treatment. Similarly in our study, all but two
patients were treated first line (96%) and the same proportion
(24%) had been treated with prior 5-FU-based adjuvant therapy.
However, the median age of the patients in our study population
was considerably higher than in the phase III studies (72 vs 64
years, respectively). Furthermore, our results concur with the
efficacy results of the BSA-calculated dose schedule of capecitabine
in a similarly elderly population (median 75 years). In a study
reported by Feliu et al (2005), 51 patients were treated with
capecitabine first line for advanced/metastatic colorectal cancer. The
response rate was 27% with an overall median survival of 11 months.
Overall fixed-dose capecitabine was well tolerated. As antici-
pated, diarrhoea and HFS were the predominant adverse effects.
The majority of adverse events resolved with treatment delay,
while a single dose reduction was required in 29% of patients and
multiple reductions in only 9%. In total, 15% of patients ceased
treatment because of adverse events and this was mainly due to
gastrointestinal events. There were no treatment-related grade 4
adverse events or deaths.
The toxicity data reported in this study are comparable to
that of the combined safety analysis of the two-phase III studies
of BSA-calculated dose schedule of capecitabine (Cassidy et al,
2002). The rates of grade 3/4 adverse events in the combined
analysis as compared to the current study of fixed-dose
capecitabine were: diarrhoea (12 vs 9%), HFS (17 vs 11%), nausea
and vomiting (2 vs 2%) and stomatitis (2 vs 0%). Therefore,
toxicity appeared to be comparable in those receiving fixed-dose
capecitabine.
In terms of exposure to capecitabine, patients received a median
6.5 treatment cycles. The total dose of capecitabine administered
during the first cycle was 56000mg, which is 12% less than would
have been administered using the currently recommended BSA-
calculated dose schedule, that is, 63350mg. The lower total dose
with the fixed-dose schedule might be expected to bias towards
reduced efficacy and improved safety, but this was not found. Dose
reduction during subsequent cycles is relatively common with
either schedule: dose reduction occurred in 34% of patients
receiving BSA-adjusted dosing with capecitabine in the phase III
trials compared with a similar percentage (38%) in our study of
fixed-dose capecitabine (Cassidy et al, 2002).
A number of studies have sought to identify patient character-
istics and laboratory parameters that might predict for 5-FU
toxicity. The second aspect of this trial was an assessment of likely
predictors of toxicity in patients treated with capecitabine. A
number of parameters were considered based on previous work
with antifolate drugs (Calvert, 2002; Niyikiza et al, 2002). These
included vitamin B12, serum and red cell folate and homocysteine.
Based on previously published work, it was anticipated that there
would not be a high incidence of grades 3 and 4 toxicity. Therefore,
we planned to group grades 0 and 1 toxicity and grades 2 and 3
toxicity for analysis. Grade 2 mucositis, diarrhoea and HFS are
significant toxicities, impacting negatively on quality of life and
often necessitate treatment interruption, and predict for greater
toxicity with subsequent courses, especially HFS. We found no
significant relationship between toxicity and baseline values for
serum vitamin B12, red cell folate or homocysteine. A significant
relationship, however, was observed between high pretreatment
concentrations of serum folate, and a higher incidence of grade 2/3
toxicity during cycle 1 (P¼0.02). This association remained
significant for the entire treatment period (P¼0.04). In particular,
a higher incidence of grade 2/3 diarrhoea and nausea and vomiting
was seen during cycle 1. These results are contrary to studies in the
antimetabolites, in which low levels of serum folate, as indicated by
a raised serum homocysteine level, were associated with worse
toxicity (Bunn et al, 2001; Niyikiza et al, 2002). This difference may
be explained by the different mechanism of action of the
antifolates. The antifolates compete with naturally occurring folate
for active moieties on folate-dependent enzymes. Depletion in the
level of intracellular folate will therefore lead to increased toxicity.
Furthermore, the level of intracellular folate feeds back to inhibit
the polyglutamation of antifolates, limiting toxicity. It could be
hypothesised that increased serum folate results in an increase in
the reduced folate pool and hence increased TS inhibition,
increased drug activity and, therefore, increased toxicity. This,
however, remains to be further elucidated. Furthermore, as only 36
folate samples were available for analysis, these results need to be
interpreted with caution and a larger study needs to be conducted
to confirm these results.
It is unclear why serum folate and not red cell folate should be
correlated with worse toxicity. Serum folate levels are indicative of
the immediate folate pool and changes with dietary intake. Red cell
folate is the polyglutamated form of folate and is a measure of
intracellular folate and therefore does not fluctuate on a daily
basis. We could speculate then that because of the addition of a
glutamate residue, red cell folate may perhaps be less mobile and
therefore be unable to participate in enzymatic reactions, while
serum folate may be more mobile.
We conclude that fixed-dose capecitabine is both an effective
and well-tolerated treatment for patients with metastatic colorectal
cancer. It allows simplification and ease of dosing, not only from
the point of dose calculation but also because the initial dose (and
any possible dose reductions) can be simply made up using the
500-mg tablet. This provides convenience for the patient and
avoids potential confusion that might lead to miss-dosing by
confusion between 500 and 150-mg tablets. The current results also
suggest that a high pretreatment concentration of serum folate
may be predictive of increased toxicity from capecitabine. This
observation requires further investigation.
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